Gilead wants state AIDS drug programs to pay significant price hikes for HIV meds

Taking stock of the drug industry, from the lab to the medicine chest

September 2, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Rich Pedroncelli/AP STAT+ | Gilead wants state AIDS drug programs to pay significant price hikes for HIV meds The move is adding to financial uncertainty surrounding Trump administration policy toward HIV treatment and prevention. By Ed Silverman STAT+ | Ionis drug lowers triglycerides, reduces pancreas damage in late-stage studies New data on the therapy showed it lowered the triglycerides of patients with a common condition, which may make it a blockbuster medication. By Jonathan Wosen STAT+ | Biotech veterans John Maraganore, Clive Meanwell launch new heart disease startup with lofty goals Clive Meanwell and John Maraganore want to harness AI and an RNAi drug to create a world without cardiovascular disease. By Allison DeAngelis Adobe STAT+ | Opinion: Make statins available without a prescription Statins are safe, effective, and cheap. They should be available without a prescription, cardiologist Vishal Khetpal writes. By Vishal Khetpal STAT+ | The key health care policies at stake in Congress' government funding fight A messy budget process looms over critical health care policies: ACA subsidies, hospital site-neutral payments, Medicare, and PBM reforms. By John Wilkerson

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser